1. National Institute for Health and Care Excellence. NICE Guidance TA288. Dapagliflozin in combination therapy for treating type 2 diabetes. Secondary NICE Guidance TA288. Dapagliflozin in combination therapy for treating type 2 diabetes. 2013. http://www.nice.org.uk/guidance/TA288/chapter/1-guidance
2. National Institute for Health and Care Excellence. NICE Guidance TA315. Canagliflozin in combination therapy for treating type 2 diabetes. Secondary NICE Guidance TA315. Canagliflozin in combination therapy for treating type 2 diabetes 2014. http://www.nice.org.uk/guidance/TA315/chapter/1-guidance
3. National Institute for Health and Care Excellence. Empagliflozin combination therapy for treating type 2 diabetes [ID641] GID-TAG441. Secondary Empagliflozin combination therapy for treating type 2 diabetes [ID641] GID-TAG441 2014. http://www.nice.org.uk/guidance/indevelopment/GID-TAG441
4. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion results of a randomized, placebo-controlled study;Polidori;Diabetes Care,2013
5. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial;Stein;Metab Clin Exp,2014